Researchers have identified antibody Z004, which was effective at neutralizing both Zika and dengue 1 and shows promise as a new potential strategy for developing a vaccine.
Researchers at Houston’s Baylor College of Medicine began Phase 2 clinical trials for a Zika vaccine that is expected to have results as early as the end of this year. The first part of phase 2 will have 90 healthy volunteers vaccinated to determine the optimal dose and injection site of the vaccine.
While more than a dozen small biotech firms and organizations are in the early stages of vaccine development against Zika, an Austrian biotech company plans to start clinical trials, based on measles vaccine technology, within the next 12 months.
Time is running out for the passage of a Zika funding bill that would help protect the nation from the Zika virus. The lack of funding has delayed the next phase in vaccine trials and hurt efforts to develop better diagnostic tools and conduct research on the effects of unborn children. For more information, click […]
A vaccine that’s safe and ready to use in people could take years, meaning that it might not be available until long after the current epidemic is over. However, several bits of good news emerged last week as scientists announced that two candidate vaccines show promise. For more information, click here
French Sanofi, the only drugmaker working on the development of a vaccine, has teamed up with Walter Reed Army Institute of Research to speed up the process. For more information, click here
A leading Brazilian biomedical research center, the U.S and the WHO are partnering to develop a vaccine for Zika. Developing a safe vaccine for pregnant women and their unborn babies will take several years. For more information, click here